Abstract

Background and Objective

Durvalumab plus tremelimumab (Durva/Treme) has recently been approved as a first-line or later-line treatment for patients with unresectable hepatocellular carcinoma (u-HCC) in Japan. We assessed the real-world outcomes of Durva/Treme for u-HCC, with a focus on treatment efficacy and safety.

Methods

We retrospectively evaluated 22 patients with u-HCC treated with Durva/Treme at Iwate Medical University during the period from 2023 to 2024, with a comparison of the clinical outcomes between patients who received Durva/Treme as first-line and later-line treatments. We further evaluated changes in the modified albumin-bilirubin (mALBI) grade during treatment.

Results

There were 10 patients in the first-line group and 12 patients in the later-line treatment group. During the follow-up with a median duration of 7.6 months, the median progression-free survival (first-line versus later-line: 4.7 months versus 2.9 months, p = 0.85), the objective response rate (0.0% versus 16.7%, p = 0.48), the disease control rate (60.0% versus 58.4%, p = 1.00), and the incidence of any adverse event (50.0% versus 75.0%, p = 0.38) were not statistically different between the two groups. The changes in the mALBI scores were not statistically significant (p = 0.75).

Conclusions

Durva/Treme may be effective and safe for patients with u-HCC, even in patients who receive Durva/Treme as a later-line treatment.

Details

Title
Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment
Author
Fujiwara, Yudai 1   VIAFID ORCID Logo  ; Kuroda, Hidekatsu 1 ; Abe, Tamami 1 ; Kakisaka, Keisuke 1 ; Nakaya, Ippeki 1 ; Ito, Asami 1 ; Watanabe, Takuya 1 ; Yusa, Kenji 1 ; Nagasawa, Tomoaki 1 ; Sato, Hiroki 1 ; Suzuki, Akiko 1 ; Endo, Kei 1 ; Yoshida, Yuichi 1 ; Oikawa, Takayoshi 1 ; Sawara, Kei 1 ; Miyasaka, Akio 1 ; Matsumoto, Takayuki 1 

1  Iwate Medical University, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate, Japan (GRID:grid.411790.a) (ISNI:0000 0000 9613 6383) 
Pages
701-710
Publication year
2024
Publication date
Dec 2024
Publisher
Springer Nature B.V.
ISSN
21991154
e-ISSN
21989788
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1007/s40801-024-00458-7
ProQuest document ID
3132717980
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.